rimonabant
Sign in to saveAlso known as A 281, SR 141716
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious neurological and psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was first-in-class.
Research
2,901 papers- Rimonabant Sanofi-Synthélabo.Current opinion in investigational drugs (London, England : 2000) · 2004
- Rimonabant--a selective CB1 antagonist.The Annals of pharmacotherapy · 2005
- Rimonabant for overweight or obesity.The Cochrane database of systematic reviews · 2006
- Rimonabant for the treatment of overweight and obese people.Health technology assessment (Winchester, England) · 2009
- Rimonabant for treating tobacco dependence.Vascular health and risk management · 2007
via PubMed
~4 min read
Encyclopedic overview
7 sectionsContents
- History
- Adverse effects
- Pharmacology
- Chemistry
- Research
- See also
- References
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious neurological and psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was first-in-class.
==History==
Excerpted from Wikipedia’s “rimonabant” article, available under the CC BY-SA 4.0 licence.